Press Release
« Back
TG Therapeutics, Inc. Announces Poster Presentations for Ublituximab (TG-1101) and TGR-1202 at the Upcoming 54th American Society of Hematology Meeting
Dec 06, 2012
TG-1101 (Ublituximab)
Waldenstrom's Macroglobulinemia Poster Presentation
- Title: Ublituximab, an Optimized Anti-CD20 Monoclonal Antibody, Demonstrates Greater NK-Mediated ADCC Than Rituximab in Waldenstrom's Macroglobulinemia Patients Supporting a Therapeutic Strategy with Ublituximab (#1654)
- Session: Lymphoma - Pre-Clinical - Chemotherapy and Biologic Agents: Poster I
-
Date/Time:
Saturday, December 8 ;5:30 PM - 7:30 pm EST -
Presenter(s): Dr.
Magali Le Garff-Tavernier , Professor Véronique Leblond, MD, PhD, et. al. Service d'Hématologie Clinique, Pitié Salpétriere,Paris, France
Non-Hodgkin Lymphoma Poster Presentation
-
Title: Ublituximab (TGTX-1101), A Novel Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Activity in Rituximab-sensitive and Rituximab—resistant B Non-Hodgkin Lymphoma (B-
NHL ) Pre-clinical In Vitro and In Vivo Models (#2756) - Session: Lymphoma - Pre-Clinical - Chemotherapy and Biologic Agents: Poster II
-
Date/Time:
Sunday, December 9 ;6:00 PM - 8:00 pm EST -
Presenter(s):
Matthew Barth , MD,Myron Czuczman , MD, et. al.Roswell Park Cancer Institute ,Buffalo, NY
CNS Lymphoma Poster Presentation
- Title: Ublituximab (TGTX-1101), a Novel, Third-Generation Anti-CD20 Antibody Demonstrates Enhanced Antitumor Activity Compared to Rituximab in Primary CNS and Intraocular Lymphoma Murine Models (#2755)
- Session: Lymphoma - Pre-Clinical - Chemotherapy and Biologic Agents: Poster II
-
Date/Time:
Sunday, December 9 ; 6:00 PM - 8:00 pm EST -
Presenter(s): Sabrina Donnou,
Sylvain Fisson , et. al. Institute National de la Santé et de la Recherche Médicale (INSERM), UMRS872,Paris, France
TGR-1202
Acute Leukemia (AML/ALL) Poster Presentation
- Title: TGR-1202 Suppresses AML and ALL Cells Via Selective Inhibition of PI3K-delta Kinase (#2610)
- Session: Acute Lymphoblastic Leukemia - Therapy, excluding Transplantation: Poster II
-
Date/Time:
Sunday, December 9 ; 6:00 PM - 8:00 pm EST -
Presenter(s):
Michael Savona , MD,Swaroop Vakkalanka , PhD, et. al. Sarah Cannon Research Institute,Nashville, TN andRhizen Pharmaceuticals, SA
Chronic Lymphocytic Leukemia (CLL) Poster Presentation
- Title: Comparison of the PI3K-delta Inhibitors TGR-1202 and GS-1101 in Inducing Cytotoxicity and Inhibiting Phosphorylation of Akt in CLL Cells in Vitro (#3914)
- Session: CLL - Biology and Pathophysiology, excluding Therapy: Poster III
-
Date/Time:
Monday, December 10 ; 6:00 PM - 8:00 pm EST -
Presenter(s):
Daphne Friedman , MD,Mark Lanasa , MD, PhD, et. al. Duke University Medical Center,Durham, NC
TG-1101 (Ublituximab) + TGR-1202
B-Cell and T-Cell Lymphoma Poster Presentation
- Title:Novel PI3K Inhibitors Demonstrated Marked Cytotoxicity in T Cell Lymphoma Models, Caused Apoptosis and Were Synergistic with A Novel Anti-CD20 Monoclonal Antibody Ublituximab in B Cell Lymphoma Models (#3725)
- Session: Lymphoma - Pre-Clinical - Chemotherapy and Biologic Agents: Poster III
-
Date/Time:
Monday, December 10 ; 6:00 PM - 8:00 pm EST -
Presenter(s):
Changchun Deng , MD, PhD,Owen A. O'Connor , MD, PhD, et. al.Center for Lymphoid Malignancies ,Columbia University Medical Center ,New York, NY
A copy of the above referenced abstracts can be viewed online through the ASH meeting website at www.hematology.org.
In addition to the poster presentations,
ABOUT TG-1101 (UBLITUXIMAB)
TG-1101 is a novel, third generation chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen found on B-lymphocytes. TG-1101 has been bioengineered for enhanced biological activity with an increased ability to trigger an immune response, delivering superior ADCC effects to aid in B-cell depletion. TG-1101 has displayed high single agent activity in a Phase I/II clinical trial in patients with relapsed Chronic Lymphocytic Leukemia, and is being developed by
ABOUT TGR-1202
TGR-1202 is a highly specific, orally available, PI3K delta inhibitor, targeting the delta isoform with nanomolar potency and several fold selectivity over the alpha, beta, and gamma isoforms of PI3K. Inhibition of PI3K delta signaling with TGR-1202 has demonstrated robust activity in numerous pre-clinical models and primary cells from patients with hematologic malignancies.
ABOUT
The
Cautionary Statement
Some of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for TG-1101 and TGR-1202 may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete pre-clinical and clinical trials for TG-1101 and TGR-1202; the risk that the data (both safety and efficacy) from future clinical trials will not coincide with the data analyses from prior pre-clinical and clinical trials; and other risk factors identified from time to time in our reports filed with the
TGTX - G
CONTACT:Source:Jenna Bosco Director- Investor RelationsTG Therapeutics, Inc. Telephone: 212.554.4484 Email: ir@tgtxinc.com
News Provided by Acquire Media